Compare UTL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UTL | SGMT |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.1M | 761.6M |
| IPO Year | 1995 | 2021 |
| Metric | UTL | SGMT |
|---|---|---|
| Price | $55.65 | $10.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $54.33 | $27.27 |
| AVG Volume (30 Days) | 84.9K | ★ 1.1M |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | ★ 1.37 | N/A |
| EPS | ★ 2.02 | N/A |
| Revenue | ★ $536,000,000.00 | $2,000,000.00 |
| Revenue This Year | $15.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.59 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $47.18 | $4.50 |
| 52 Week High | $58.33 | $11.45 |
| Indicator | UTL | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 51.36 |
| Support Level | $50.41 | $9.95 |
| Resistance Level | $57.80 | $11.23 |
| Average True Range (ATR) | 1.15 | 0.68 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 37.67 | 47.52 |
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.